The Adoption of Radiomics and machine learning improves the diagnostic processes of women with Ovarian MAsses (the AROMA pilot study)

被引:39
作者
Chiappa, Valentina [1 ]
Bogani, Giorgio [1 ]
Interlenghi, Matteo [2 ]
Salvatore, Christian [3 ]
Bertolina, Francesca [1 ]
Sarpietro, Giuseppe [1 ]
Signorelli, Mauro [1 ]
Castiglioni, Isabella [4 ]
Raspagliesi, Francesco [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori Milano, Dept Gynecol Oncol, Via Venezian 1, I-20133 Milan, Italy
[2] CNR, Inst Mol Bioimaging & Physiol, Milan, Italy
[3] DeepTrace Technol SRL, Milan, Italy
[4] Univ Milano Bicocca, Dipartimento Fis G Occhialini, Milan, Italy
关键词
Radiomics; Ultrasound; Ovarian cancer; Risk of malignancy; Ovarian masses; Predictive model; ADNEX MODEL; EXTERNAL VALIDATION; CANCER; ULTRASOUND; RADIOGENOMICS;
D O I
10.1007/s40477-020-00503-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To develop and evaluate the performance of a radiomic and machine learning model applied to ultrasound images in predicting the risk of malignancy of ovarian masses (OMs). Methods Single-center retrospective evaluation of consecutive patients who underwent transvaginal ultrasound (US) with images storage and surgery for ovarian masses. Radiomics methodology was applied to US images according to the International Biomarker Standardization Initiative guidelines. OMs were divided into three homogeneous groups: solid, cystic and motley. TRACE4 (c) radiomic platform was used thus obtaining a full-automatic radiomic workflow. Three different classification systems were created and accuracy, sensitivity, specificity, AUC and standard deviation were defined for each group. Results A total of 241 women were recruited. OMs were divided in the three groups: 95 (39.5%) solid, 66 (27.5%) cystic, 80 (33%) motley. For solid OMs, 269 radiomic features were used for the training-validation-testing of the model with accuracy 80%, sensitivity 78%, specificity 83%, AUC 87%. For cystic OMs, 278 radiomic features were used for the training-validation-testing of the model with accuracy 87%, sensitivity 75%, specificity 90%, AUC 88%. For mixed OMs, 306 radiomic features were used for the training-validation-testing of the model with accuracy 81%, sensitivity 81%, specificity 81%, AUC 89%. Conclusion Radiomics is a promising tool in improving preoeprative work-up of women diagnosed with OMs. Even in the absence of the subjective impression of expert ultrasound examiner, radiomics allows to easily identify patients with ovarian cancer. Future validation studies on larger series are needed.
引用
收藏
页码:429 / 437
页数:9
相关论文
共 31 条
  • [1] Ovarian Tissue Characterization in Ultrasound: A Review
    Acharya, U. Rajendra
    Molinari, Filippo
    Sree, S. Vinitha
    Swapna, G.
    Saba, Luca
    Guerriero, Stefano
    Suri, Jasjit S.
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2015, 14 (03) : 251 - 261
  • [2] Acharya UR, 2012, IEEE ENG MED BIO, P4446, DOI 10.1109/EMBC.2012.6346953
  • [3] Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
    Aerts, Hugo J. W. L.
    Velazquez, Emmanuel Rios
    Leijenaar, Ralph T. H.
    Parmar, Chintan
    Grossmann, Patrick
    Cavalho, Sara
    Bussink, Johan
    Monshouwer, Rene
    Haibe-Kains, Benjamin
    Rietveld, Derek
    Hoebers, Frank
    Rietbergen, Michelle M.
    Leemans, C. Rene
    Dekker, Andre
    Quackenbush, John
    Gillies, Robert J.
    Lambin, Philippe
    [J]. NATURE COMMUNICATIONS, 2014, 5
  • [4] [Anonymous], 2016, FDA REC US SCREEN TE
  • [5] Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
    Bagnoli, Marina
    Canevari, Silvana
    Califano, Daniela
    Losito, Simona
    Di Maio, Massimo
    Raspagliesi, Francesco
    Carcangiu, Maria Luisa
    Toffoli, Giuseppe
    Cecchin, Erika
    Sorio, Roberto
    Canzonieri, Vincenzo
    Russo, Daniela
    Scognamiglio, Giosue
    Chiappetta, Gennaro
    Baldassarre, Gustavo
    Lorusso, Domenica
    Scambia, Giovanni
    Zannoni, Gian Franco
    Savarese, Antonella
    Carosi, Mariantonia
    Scollo, Paolo
    Breda, Enrico
    Murgia, Viviana
    Perrone, Francesco
    Pignata, Sandro
    De Cecco, Loris
    Mezzanzanica, Delia
    [J]. LANCET ONCOLOGY, 2016, 17 (08) : 1137 - 1146
  • [6] Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study
    Froyman, Wouter
    Landolfo, Chiara
    De Cock, Bavo
    Wynants, Laure
    Sladkevicius, Povilas
    Testa, Antonia Carla
    Van Holsbeke, Caroline
    Domali, Ekaterini
    Fruscio, Robert
    Epstein, Elisabeth
    dos Santos Bernardo, Maria Jose
    Franchi, Dorella
    Kudla, Marek Jerzy
    Chiappa, Valentina
    Alcazar, Juan Luis
    Leone, Francesco Paolo Giuseppe
    Buonomo, Francesca
    Hochberg, Lauri
    Coccia, Maria Elisabetta
    Guerriero, Stefano
    Deo, Nandita
    Jokubkiene, Ligita
    Kayser, Jeroen
    Coosemans, An
    Vergote, Ignace
    Verbakel, Jan Yvan
    Bourne, Tom
    Van Calster, Ben
    Valentin, Lil
    Timmerman, Dirk
    [J]. LANCET ONCOLOGY, 2019, 20 (03) : 448 - 458
  • [7] Kaijser J, 2015, FACTS VIEWS VIS OBGY, V7, P42
  • [8] Quantitative ultrasound of trapezius muscle involvement in myofascial pain: comparison of clinical and healthy population using texture analysis
    Kumbhare, Dinesh
    Shaw, Saurabh
    Ahmed, Sara
    Noseworthy, Michael D.
    [J]. JOURNAL OF ULTRASOUND, 2020, 23 (01) : 23 - 30
  • [9] A new computer-aided diagnostic tool for non-invasive characterisation of malignant ovarian masses: results of a multicentre validation study
    Lucidarme, Olivier
    Akakpo, Jean-Paul
    Granberg, Seth
    Sideri, Mario
    Levavi, Hanoch
    Schneider, Achim
    Autier, Philippe
    Nir, Dror
    Bleiberg, Harry
    [J]. EUROPEAN RADIOLOGY, 2010, 20 (08) : 1822 - 1830
  • [10] Radiogenomics: What It Is and Why It Is Important
    Mazurowski, Maciej A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2015, 12 (08) : 862 - 866